On January 6, 2021 Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LTB4) systems are implicated, reported that Clive Richardson, Chief Executive Officer, will participate in the following two upcoming virtual investor conferences (Press release, Akari Therapeutics, JAN 6, 2021, View Source [SID1234573545]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference: H.C. Wainwright BioConnect Conference

Date & Time: The Company’s presentation will be available on demand starting January 11, 2021 through the Company’s website.

Conference: ICR Conference 2021

Date & Time: Thursday, January 14, 2021 at 10:00 a.m. ET.

Investors interested in arranging a virtual meeting with the Company’s management during the ICR Conference 2021 should contact the ICR conference coordinator or [email protected]. Webcasts of both presentations will be available by visiting ‘Events’ in the Investor Relations section on the Company’s website at www.akaritx.com.